Systemic treatment of HCC in special populations

Lorenza Rimassa; Nicola Personeni; Carolin Czauderna; Friedrich Foerster; Peter Galle

doi:10.1016/j.jhep.2020.11.026

Systemic treatment of HCC in special populations

Lorenza Rimassa^*, Nicola Personeni, Carolin Czauderna, Friedrich Foerster, Peter Galle

^*Corresponding author for this work

Department of Internal Medicine I

103 Citations (Scopus)

Abstract

Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirrhosis (Child-Pugh B and C), a significant bleeding history, vascular invasion or portal vein thrombosis, as well as the elderly, those on haemodialysis, and those after solid organ transplantation. The article highlights relevant knowledge gaps and current clinical challenges. To improve the safety and efficacy of HCC treatment in these subgroups, future trials should be designed to specifically include patients with comorbidities.

Original language	English
Journal	Journal of Hepatology
Volume	74
Issue number	4
Pages (from-to)	931-943
Number of pages	13
ISSN	0168-8278
DOIs	https://doi.org/10.1016/j.jhep.2020.11.026
Publication status	Published - 04.2021

Funding

LR reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel fees from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks. NP reports receiving consulting fees from Amgen, Merck Serono, Servier; lectures fees from AbbVie, Gilead, Lilly; travel fees from Amgen, ArQule; and institutional research funding from Basilea, Merck Serono, Servier. CC reports receiving consulting fees from MSD and lectures fees from EISAI. FF reports receiving consulting fees from Roche; lectures fees from Lilly and Pfizer. PRG reports receiving consulting and lectures fees from Adaptimmune, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Lilly, MSD, Roche, Sirtex.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.jhep.2020.11.026

Cite this

@article{f2c90542cc1a4cb58afd730c06f9a302,

title = "Systemic treatment of HCC in special populations",

abstract = "Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirrhosis (Child-Pugh B and C), a significant bleeding history, vascular invasion or portal vein thrombosis, as well as the elderly, those on haemodialysis, and those after solid organ transplantation. The article highlights relevant knowledge gaps and current clinical challenges. To improve the safety and efficacy of HCC treatment in these subgroups, future trials should be designed to specifically include patients with comorbidities.",

author = "Lorenza Rimassa and Nicola Personeni and Carolin Czauderna and Friedrich Foerster and Peter Galle",

note = "Publisher Copyright: {\textcopyright} 2020 European Association for the Study of the Liver",

year = "2021",

month = apr,

doi = "10.1016/j.jhep.2020.11.026",

language = "English",

volume = "74",

pages = "931--943",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Systemic treatment of HCC in special populations

AU - Rimassa, Lorenza

AU - Personeni, Nicola

AU - Czauderna, Carolin

AU - Foerster, Friedrich

AU - Galle, Peter

PY - 2021/4

Y1 - 2021/4

N2 - Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirrhosis (Child-Pugh B and C), a significant bleeding history, vascular invasion or portal vein thrombosis, as well as the elderly, those on haemodialysis, and those after solid organ transplantation. The article highlights relevant knowledge gaps and current clinical challenges. To improve the safety and efficacy of HCC treatment in these subgroups, future trials should be designed to specifically include patients with comorbidities.

AB - Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirrhosis (Child-Pugh B and C), a significant bleeding history, vascular invasion or portal vein thrombosis, as well as the elderly, those on haemodialysis, and those after solid organ transplantation. The article highlights relevant knowledge gaps and current clinical challenges. To improve the safety and efficacy of HCC treatment in these subgroups, future trials should be designed to specifically include patients with comorbidities.

UR - https://www.scopus.com/pages/publications/85098144537

UR - https://www.mendeley.com/catalogue/2178c2fc-1fb0-3ba2-aabc-687963fcdf21/

U2 - 10.1016/j.jhep.2020.11.026

DO - 10.1016/j.jhep.2020.11.026

M3 - Scientific review articles

C2 - 33248171

AN - SCOPUS:85098144537

SN - 0168-8278

VL - 74

SP - 931

EP - 943

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 4

ER -

Systemic treatment of HCC in special populations

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this